SEXUAL HEALTH
Bremelanotide (PT-141) FDA-approved bremelanotide medicine for acquired, generalized hypoactive sexual desire disorder in eligible premenopausal women. It is not approved for male sexual performance.
Form Subcutaneous injection
Product status FDA-approved product and dosage form reference
Availability Subject to clinical and pharmacy review
Patient pricing $88.00 per unit BEFORE TREATMENT
A clinical decision, Product selection, formulation and any prescription require an independent clinical evaluation. Catalog inclusion is not a recommendation or a guarantee of a prescription.
Your provider determines whether treatment is appropriate and explains any required monitoring and follow-up.
Reference: Official product information . Reviewed September 17, 2026. Approval is specific to this medicine and its labeled uses.
